Biofrontera Inc. (BFRI)
NASDAQ: BFRI · Real-Time Price · USD
1.010
0.00 (0.00%)
At close: Jul 2, 2026, 4:00 PM EDT
1.030
+0.020 (1.98%)
After-hours: Jul 2, 2026, 7:23 PM EDT
Biofrontera Revenue
Biofrontera had revenue of $10.08M in the quarter ending March 31, 2026, with 17.42% growth. This brings the company's revenue in the last twelve months to $33.12M, down -12.84% year-over-year. In the year 2025, Biofrontera had annual revenue of $41.71M with 11.75% growth.
Revenue (ttm)
$33.12M
Revenue Growth
-12.84%
P/S Ratio
0.30
Revenue / Employee
$459,585
Employees
94
Market Cap
12.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 41.71M | 4.38M | 11.75% |
| Dec 31, 2024 | 37.32M | 3.25M | 9.54% |
| Dec 31, 2023 | 34.07M | 5.40M | 18.82% |
| Dec 31, 2022 | 28.67M | 4.57M | 18.98% |
| Dec 31, 2021 | 24.10M | 5.25M | 27.86% |
| Dec 31, 2020 | 18.85M | -7.33M | -28.01% |
| Dec 31, 2019 | 26.18M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Rockwell Medical | 67.68M |
| Aytu BioPharma | 56.60M |
| cbdMD | 19.98M |
| InMed Pharmaceuticals | 4.94M |
| China Pharma Holdings | 3.99M |
| TherapeuticsMD | 3.35M |
| China SXT Pharmaceuticals | 1.14M |
| Akanda | 258.08K |
BFRI News
- 21 days ago - Biofrontera Transcript: AGM 2026 - Transcripts
- 5 weeks ago - Biofrontera Transcript: Lytham Partners Spring 2026 Investor Conference - Transcripts
- 6 weeks ago - Biofrontera Inc. to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - GlobeNewsWire
- 6 weeks ago - Biofrontera downgraded to Speculative Buy from Buy at Benchmark - TheFly
- 7 weeks ago - Biofrontera Earnings Call Transcript: Q1 2026 - Transcripts
- 7 weeks ago - Biofrontera Earnings release: Q1 2026 - Filings
- 7 weeks ago - Biofrontera Quarterly report: Q1 2026 - Filings
- 7 weeks ago - Biofrontera Launches Second Annual “Hats On” Campaign to Raise Awareness of Actinic Keratosis - GlobeNewsWire